Inclusion Criteria:

- Histologically confirmed chronic myelogenous leukemia

- Philadelphia chromosome positive by cytogenetics OR fluorescent in situ
hybridization

- Accelerated or non-lymphoid blastic phase

- Performance status - ECOG 0-2

- Bilirubin no greater than 2 times upper limit of normal (ULN)

- AST no greater than 2 times ULN

- Creatinine less than 2.0 mg/dL

- Normal cardiac function

- No New York Heart Association class III or IV heart disease

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No prior decitabine

- At least 2 weeks since other prior chemotherapy (unless there is evidence of rapidly
progressive disease) and recovered

- Concurrent hydroxyurea allowed during the first 2 courses of study therapy in
patients with rapidly progressing disease

- Prior imatinib mesylate allowed

- Patients who received at least 4 weeks of prior imatinib mesylate must have
failed therapy, as evidenced by resistance after 8 weeks or disease progression

- No concurrent grapefruit or grapefruit juice